Insulinomas are predominantly benign (~90%), pancreatic neuroendocrine tumours characterized by hyperinsulinaemic hypoglycaemia. They usually present as a small (<2 cm), well-demarcated, solitary nodule that can arise in any part of the organ. can effectively control tumour growth or provide symptomatic benefit in metastatic disease, while cytotoxic chemotherapy can be used in patients with higher-grade tumours. This review considers the developments in the medical and other nonsurgical management options for cases refractory to standard medical management. Early referral to a dedicated neuroendocrine multidisciplinary team is critical considering the array of medical, oncological, interventional radiological and nuclear medical options. We discuss the evolving armamentarium for insulinomas when standard medical therapy fails.
| Diagnosis of insulinomas
The presence of Whipple's triad: symptoms and signs of hypoglycaemia with low plasma glucose levels, which are reversed by the administration of carbohydrate, are the characteristic diagnostic features. The evaluation and management of hypoglycaemia in patients with evidence of Whipple's triad has been clearly described. 3 Hyperinsulinaemic hypoglycaemia should be suspected in an otherwise fit and well individual after exclusion of medication use (oral hypoglycaemic agents, insulin administration), factitious hypoglycaemia, noninsulinoma pancreatogenous hypoglycaemia and rarely nonislet cell tumours. 4 The most common cause of hyperinsulinaemic hypoglycaemia in adults is an insulinoma. Hypoglycaemia occurs primarily in the fasting state, although occasionally only in the postprandial period, and can pose a significant management challenge and cause of morbidity. 
| Localization of disease
Having confirmed the biochemical diagnosis, localization of disease can be challenging. Conventional imaging (ie, CT/MRI) and, if available, endoscopic ultrasound form the basis of localization and diagnosis of suspected insulinomas.
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Ga-DOTATATE PET-CT has a clear place in localizing insulinomas because of the high affinity of the In-octreotide). 6 Glucagon-like peptide-1 receptors (GLP1-R) are also highly expressed in almost all benign insulinomas, and so recently,
we have seen the application of 68 Ga-DOTA-exendin 4 PET-CT to facilitate the localization of occult insulinomas. 7 In contrast, malignant insulinoma often lacks these GLP1-R. 8 Once localized, surgical resection of sporadic insulinomas is standard treatment as most tumours are small (<2 cm), benign and can be surgically cured; however, there is an associated high risk of complications and only limited patients may be eligible. 9 
| Classification of pNETs
The management and prognosis of pNETs is governed by the size, histological grade and disease staging. 10 
| THERAPEUTIC OPTIONS AVAILABLE FOR INSULINOMAS
Recent consensus guidance has been published on the management of functional and nonfunctional pNETs. [14] [15] [16] Based on the suspected aggressiveness of the disease, patients may be offered different treatment regimens ( Figure 1 ). In insulinomas of genetic aetiology, the clinical features may differ (eg, earlier age of onset, multifocal nature of disease, natural history) compared to sporadic insulinomas, and this should be considered when considering treatment options.
| Surgery
Surgery is the treatment of choice whenever possible. It provides both symptomatic control and long-term cure. In the presence of primary and well-differentiated metastatic functional pNETs, surgery with curative intent must always be considered, even if there is liver or lymph node involvement. For unresectable metastatic disease, the resection of the functional primary NET, like insulinomas, is controversial due to the marginal improvement in symptomatic control in this palliative setting, and the potential morbidities associated with the surgery.
Despite this, studies have suggested that there could possibly be improvement of long-term overall and progression-free survival after primary tumour resection in this advanced stage. 
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| Conventional advice and medical therapy
| Diazoxide
Medical treatment is available to those who are unable or unwilling to undergo surgical treatment and as an adjunct to other treatment modalities. Diazoxide, an antihypertensive benzothiadiazine which acts as a potassium channel activator, has formed the mainstay of medical management in symptomatic control of insulinomas for over 30 years. 19 Diazoxide is generally regarded as first-line treatment for control of hypoglycaemia in patients with insulinomas, frequently used preoperatively when dietary and lifestyle advice fails to prevent hypoglycaemia. Potential glycaemic mechanisms include inhibition of insulin release by direct action on β-cells through the stimulation of α-adrenergic receptors 20 or increasing hepatic gluconeogenesis and reduced skeletal muscle glucose uptake. 21 Initiation doses of 50-300 mg daily titrated to a maximum daily dose of 600 mg (higher doses may be used in refractory hypoglycaemia) are used. Unfortunately, side effects are common (eg, fluid retention, hirsutism, headache, gastrointestinal upset, rash) but usually not problematic, and it offers symptom control in about 50%-60% of patients. 22 Long-term treatment appears to be safe.
| Somatostatin analogues
Somatostatin, produced in the pancreatic δ-cells, acts as a paracrine regulator of insulin and glucagon secretion and regulates cell proliferation, via interaction with five different (G-protein-coupled) somatostatin receptors (SSTR [1] [2] [3] [4] [5] 
Antiproliferative effects
The antiproliferative effect of SSAs in the treatment for NETs was demonstrated in two major randomized, placebo-controlled studies:
PROMID (octreotide LAR) and CLARINET (lanreotide ; Table S1 ).
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In PROMID, 85 patients with well-differentiated midgut NETs were randomly assigned to receive octreotide LAR 30 mg vs. placebo. 
| OPTIONS FOR REFRACTORY CASES
In patients with refractory insulinomas, whose symptoms have not responded to diazoxide or SSAs, there are several treatment options available. The optimal sequence for these treatments is unknown.
| Novel somatostatin analogues (pasireotide)
Mechanism of action
Pasireotide is a novel multireceptor somatostatin analogue that binds with high affinity to four somatostatin receptor subtypes Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that is involved in the signal transduction response to insulin, growth factor and other nutrients via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. 34 In patients with pNETs, dysregulation of the Akt/mTOR pathway occurs, resulting in unrestrained cell growth, proliferation and reduced apoptosis.
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Mechanism for the hyperglycaemic action of everolimus
The Akt/mTOR pathway is also involved in the control of glucose homeostasis and dysregulated mTOR signalling is implicated in peripheral insulin (Figures 3 and 4) . 36 mTOR inhibition pharmacologically has a similar effect, resembling a state of peripheral insulin resistance. 37 Everolimus has also been shown to directly inhibit (pro)insulin secretion by insulinoma cells, and this effect has been suggested from clinical experience. 37 Thus, everolimus as an mTOR inhibitor has an effect on tumour progression but will have secondary effects correcting hypoglycaemia.
Evidence to support everolimus use in pNETs
Kulke was the first to report symptomatic relief of hypoglycaemia with everolimus 38 associated with a reduction in insulin levels with numerous subsequent case reports supporting this.
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Efficacy and safety
The efficacy and safety of everolimus in the treatment for NETs of different origins has been explored in the RADIANT trials (Table S2A) . [40] [41] [42] In the phase 3 RADIANT-3 trial (RAD001 in advanced neuroendocrine tumours), patients with advanced pancreatic NETs were randomized to receive everolimus, 10 mg oral daily or placebo. 
Positioning in the clinical pathway
Whereas tumour remissions are rare with everolimus, disease stabilization is observed in a high proportion of patients (60%-80%). Lack of head-to-head trials means that everolimus has mostly been used in advanced metastatic disease after the failure of SSAs and/or systemic chemotherapies and is generally reserved for progressive disease due to potential toxicities.
| Sunitinib (a tyrosine kinase inhibitor)
Mechanism of action
Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor.
Sunitinib displays antiangiogenic and antitumour activity by inhibiting a number of molecular pathways involved in angiogenesis. (Table S2B) . 48 The trial was discontinued prematurely as sunitinib clearly offered improvements Unfortunately, only 2 patients receiving sunitinib had an insulinoma and the outcome of these particular patients was not described.
Unlike everolimus, this drug does not appear to have a direct action on glycaemic control.
Side effects
Cutaneous adverse events include mucositis, rash and hand-foot syndrome (HFS), characterized by palmar-plantar lesions. The most frequent side effects reported include diarrhoea, nausea, vomiting, asthenia and fatigue. Hypertension and neutropenia are the most frequent serious side effects reported. Evidence suggests that sunitinib can worsen hypoglycaemia. 49 
Positioning in the clinical pathway
Despite the reported benefits of PFS in pNETs reported with sunitinib, the consequences of worsened hypoglycaemia may outweigh such benefits specifically in malignant insulinomas.
| Cytotoxic chemotherapy
For patients with highly proliferating, rapidly progressive and/or symptomatic pancreatic NETs, cytotoxic chemotherapy may yield greater tumour shrinkage than SSAs or molecularly targeted agents.
5-Fluorouracil (5-FU), doxorubicin and streptozocin have commonly
been implicated in the treatment for inoperable malignant insulinomas. 50 Other agents (dacarbazine, cisplatin, etoposide, capecitabine and temozolomide) have also been evaluated. These combination treatments may help symptom control and have resulted in an objective response of 6%-70% of patients with pNETs; however, these studies included small numbers of insulinomas and a significant proportion of patients responded poorly with significant toxicity. Limited case series and reports describe the use of ethanol ablation and describe a relatively strong safety profile with promising results in small, localized disease (Table 1) . 59 and amylase. [59] [60] [61] [62] [63] [64] [65] [66] Severe adverse events such as pancreatitis have been reported in limited cases. 61 However, the advantage is that it is a minimally invasive procedure, is associated with a shorter hospital stay and is associated with a lower risk of complications. 
F I G U R E 4 Direct and indirect mechanisms of action of everolimus in insulinoma
| Embolization
In patients with a large hepatic burden of disease, hepatic resection and hepatic artery embolization (bland embolization, chemoembolization and radio-embolization) may also be considered with the intention of ameliorating clinical symptoms. Selective embolization of peripheral arteries induces temporary, but complete ischaemia. 68 Due to the small number of metastatic insulinomas, there are (Table S3) . 72 Treatment with
177
Lu-DOTATATE resulted in markedly longer PFS and a significantly higher response rate than the treatment with high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumours. In this study, median PFS was 8 months on the high-dose octreotide arm and was not yet reached on the 177 Lu-DOTATATE arm, translating to a 79% improvement in PFS (P < .00001).
Outcomes may be determined by patient characteristics including the amount of SSTR uptake at diagnosis 71 and tumour/liver burden.
There have been two small case series of patients with metastatic insulinoma that have demonstrated that PRRT can control hyperinsulinaemic hypoglycaemia: euglycaemia persisted even in the face of tumour progression, suggesting that favourable symptomatic responses can be observed even with no objective evidence of tumour response.
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Side effects
Peptide receptor radionuclide therapy is generally well tolerated.
Acute side effects are usually mild and include nausea and gastrointestinal upset. Importantly rare but serious side effects may occur, including severe bone marrow disease (pancytopenia, acute myelogenous leukaemia, myelodysplastic syndrome) and renal toxicity. 
Positioning in the clinical pathway
In general, use of PRRT follows failed first-line medical therapy 
